Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Raises Dividend to $0.94 Per Share

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced a quarterly dividend on Friday, January 30th. Investors of record on Friday, February 20th will be paid a dividend of 0.94 per share by the biopharmaceutical company on Thursday, March 5th. This represents a c) annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, February 20th. This is a 6.8% increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88.

Regeneron Pharmaceuticals has a dividend payout ratio of 8.9% indicating that its dividend is sufficiently covered by earnings. Analysts expect Regeneron Pharmaceuticals to earn $38.02 per share next year, which means the company should continue to be able to cover its $3.52 annual dividend with an expected future payout ratio of 9.3%.

Regeneron Pharmaceuticals Trading Down 1.1%

NASDAQ REGN traded down $7.99 during trading hours on Friday, hitting $741.45. 1,317,463 shares of the company’s stock were exchanged, compared to its average volume of 923,102. The firm has a market cap of $77.93 billion, a price-to-earnings ratio of 17.76, a PEG ratio of 1.96 and a beta of 0.39. The stock has a 50-day simple moving average of $758.68 and a 200 day simple moving average of $648.66. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 1-year low of $476.49 and a 1-year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The firm had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period in the prior year, the business earned $12.07 EPS. On average, equities analysts forecast that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the sale, the vice president directly owned 4,233 shares in the company, valued at $2,757,503.19. This represents a 9.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the transaction, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. This trade represents a 46.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 7.02% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in Regeneron Pharmaceuticals by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company’s stock valued at $7,004,838,000 after acquiring an additional 26,884 shares during the last quarter. State Street Corp boosted its holdings in shares of Regeneron Pharmaceuticals by 0.9% in the 2nd quarter. State Street Corp now owns 4,832,002 shares of the biopharmaceutical company’s stock worth $2,536,801,000 after purchasing an additional 42,343 shares in the last quarter. Dodge & Cox increased its position in shares of Regeneron Pharmaceuticals by 18.9% during the 3rd quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock valued at $2,558,804,000 after purchasing an additional 724,562 shares during the last quarter. Franklin Resources Inc. raised its stake in shares of Regeneron Pharmaceuticals by 6.0% during the third quarter. Franklin Resources Inc. now owns 2,453,143 shares of the biopharmaceutical company’s stock worth $1,379,329,000 after acquiring an additional 139,647 shares in the last quarter. Finally, Capital World Investors raised its position in Regeneron Pharmaceuticals by 1.6% in the 3rd quarter. Capital World Investors now owns 1,998,366 shares of the biopharmaceutical company’s stock worth $1,123,609,000 after purchasing an additional 32,348 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.